Perigon Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Perigon Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,590	Closed	-$367K	–	1379
2025 Q4	$367K	Buy	2,590 +78	+3%	+$11.3K	0.01%	941
2025 Q3	$353K	Buy	+2,512	New	+$340K	0.01%	883
2021 Q1	–	Sell	-210	Closed	-$20K	–	835
2020 Q4	$20K	Buy	+210	New	+$20.3K	﹤0.01%	1053

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perigon Wealth Management's NBIX Position: Q1 2026 in Review

Perigon Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 2,590 shares — an estimated $367K sold.

Perigon Wealth Management first reported a position in NBIX in Q4 2020 and held it in 3 quarters. The position peaked at $367K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Perigon Wealth Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Perigon Wealth Management sold 2,590 Neurocrine Biosciences shares in Q1 2026, an estimated $367K.
Perigon Wealth Management first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 3 quarters.
Perigon Wealth Management's Neurocrine Biosciences position peaked at $367K in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Perigon Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.